Murer, Carla
Sgier, David
Mettler, Sofia Kyonhi
Guillet, Carole
Maul, Julia-Tatjana
Djamei, Vahid
Navarini, Alexander A.
Anzengruber, Florian
Funding for this research was provided by:
Celgene
Article History
Received: 19 December 2019
Revised: 19 February 2020
Accepted: 28 March 2020
First Online: 12 April 2020
Compliance with ethical standards
:
: C.M. reports no conflict of interest. D.S. is a former employee of Celgene Inc., but has no conflict of interest. S.M has no conflict of interest. C.G has no conflicts of interest. J-T. M. is an employee of USZ and received a “filling the GAP” stipend. V.D. has honoraria from AbbVie, Celgene, Eli Lilly, Leo Pharma, Novartis and Sanofi. A. A. N was funded by the Promedica and Bruno-Bloch Foundation, as well as Hochspezialisierte Medizin 2 of the Kanton Zürich, Switzerland. He is also on the advisory board of AbbVie, Pfizer, Novartis, Celgene, MSD and Galderma and has received grants from AbbVie, Novartis, Celgene and others. F.A. has received honoraria from Abbvie, Celgene, Leo Pharma, Galderma, Eli Lilly, Janssen-Cilag, Novartis, Galderma and Almirall, but has no financial interest, nor holds any shares of any pharmaceutical company.